Loading provider…
Loading provider…
Hematology & Oncology Physician in Franklin, TN
NPI: 1336296136Primary Practice Location
ASCENSION SAINT THOMAS HOSPITAL
2000 Church St, Nashville, TN
Primary Employer
Tennessee Oncology - Nashville St Thomas Midtown
tnoncology.com
HQ Phone
Get MD Todd's Phone Numberphone_androidMobile
Get MD Todd's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 36415Insertion of needle into vein for collection of blood sample | 381 | 1,651 |
| 2 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 377 | 1,704 |
| 3 | 80053Blood test, comprehensive group of blood chemicals | 375 | 1,381 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 211 | 716 |
| 5 | 99214Established patient office or other outpatient visit, 30-39 minutes | 186 | 277 |
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Authors: Rebecca Heist, Daniel Morgensztern, Karen Kelly, David Camidge, John Strickler
Publication Date: 2021-02-26
Lead Sponsor: GlaxoSmithKline
Collaborators: Merck Sharp & Dohme LLC
Intervention / Treatment: DRUG: Docetaxel, DRUG: Pembrolizumab, DRUG: Pemetrexed, DRUG: Bintrafusp alfa, DRUG: Dostarlimab, DRUG: GSK3174998, DRUG: Cobolimab, DRUG: feladilimab (GSK3359609), DRUG: Paclitaxel plus Carboplatin, DRUG: Gemcitabine plus Carboplatin, DRUG: Fluorouracil (5-FU) plus carboplatin or cisplatin
Lead Sponsor: TopAlliance Biosciences
Collaborators: Shanghai Junshi Bioscience Co., Ltd.
Intervention / Treatment: BIOLOGICAL: Part A, BIOLOGICAL: Part B
Lead Sponsor: Deciphera Pharmaceuticals, LLC
Intervention / Treatment: DRUG: Vimseltinib
Publication Date: 2020-05-16